(+)-VINCRISTINE
Myeloproliferative Disorder
The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Myeloproliferative Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan OHSU Knight Cancer Institute | Phase 2 | BB |
Campath University of Chicago | Phase 2 | B |
Gm-Csf Beth Israel Deaconess Medical Center | Phase 2 | B |
Equine Atg Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Tocilizumab Memorial Sloan Kettering Cancer Center | Phase 2 | B |
View all 9 →
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →